Basecamp Research Secures $60M to Revolutionize AI Drug Discovery with Broad Institute Partnership

Funding:
Basecamp Research has raised $60 million in a Series B funding round led by Singular, a Paris-based firm, to further its AI drug discovery efforts.

Partnership:
The company has entered into a multi-year collaboration with Dr. David R. Liu and the Broad Institute, a major biomedical research center affiliated with MIT and Harvard, to develop "programmable" genetic medicines.

AI Approach:
Basecamp Research aims to build a "GPT for biology" by gathering primary data from around the world and combining it with AI to create models that can provide insights into biology beyond human capabilities.

Global Data Collection:
The startup is collecting data from diverse natural environments, such as hot springs and volcanoes, to build comprehensive models of biological systems.

Commercial Applications:
Basecamp Research has already partnered with over 100 organizations across 25 countries and is working with companies like Procter & Gamble to develop sustainable products using its AI platform.

Future Plans:
The company plans to use the funding to expand its database and AI capabilities, focusing on drug discovery and other challenges related to understanding and utilizing the natural world.